Teva Pharmaceutical Industries 관리
관리 기준 확인 2/4
Teva Pharmaceutical Industries CEO는 Richard Francis, Jan2023 에 임명되었습니다 의 임기는 1.83 년입니다. 총 연간 보상은 $ 25.71M, 6.2% 로 구성됩니다. 6.2% 급여 및 93.8% 보너스(회사 주식 및 옵션 포함). 는 $ 2.11M 가치에 해당하는 회사 주식의 0.011% 직접 소유합니다. 2.11M. 경영진과 이사회의 평균 재임 기간은 각각 2.7 년과 7.3 년입니다.
주요 정보
Richard Francis
최고 경영자
US$25.7m
총 보상
| CEO 급여 비율 | 6.2% |
| CEO 임기 | 1.8yrs |
| CEO 소유권 | 0.01% |
| 경영진 평균 재임 기간 | 2.7yrs |
| 이사회 평균 재임 기간 | 7.3yrs |
최근 관리 업데이트
Recent updates
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S
Nov 17
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$959m |
| Jun 30 2024 | n/a | n/a | -US$453m |
| Mar 31 2024 | n/a | n/a | -US$478m |
| Dec 31 2023 | US$26m | US$2m | -US$559m |
보상 대 시장: Richard 의 총 보상 ($USD 25.71M )은 US 시장( $USD 12.66M ).
보상과 수익: Richard 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.
CEO
Richard Francis (56 yo)
1.8yrs
테뉴어
US$25,706,880
보상
Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 1.8yrs | US$25.71m | 0.011% $ 2.1m | |
| Executive VP & CFO | 4.9yrs | US$4.94m | 0.064% $ 12.4m | |
| Executive Vice President of International Markets Commercial | 3.3yrs | US$3.73m | 0.028% $ 5.4m | |
| Executive Vice President of European Commercial | 7yrs | US$5.16m | 0% $ 0 | |
| Executive Vice President of Global Operations | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Accounting Officer | 3yrs | 데이터 없음 | 0.00046% $ 89.2k | |
| Head of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Legal Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive VP & CHRO | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Internal Auditor | 10.5yrs | 데이터 없음 | 데이터 없음 |
2.7yrs
평균 재임 기간
53yo
평균 연령
경험이 풍부한 관리: TEVA 의 관리팀은 경험 ( 2.7 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | no data | US$25.71m | 0.011% $ 2.1m | |
| Independent Chairman of the Board | 9.8yrs | US$539.99k | 0.036% $ 7.0m | |
| Independent Director | 15.8yrs | US$340.00k | 0.18% $ 35.9m | |
| Independent Director | 9.2yrs | US$355.00k | 0.0094% $ 1.8m | |
| Independent Director | 7.3yrs | US$340.00k | 0.0084% $ 1.6m | |
| Independent Director | 9.2yrs | US$330.00k | 0.0091% $ 1.8m | |
| Independent Director | 4.4yrs | US$325.46k | 0.0056% $ 1.1m | |
| Independent Director | 3.1yrs | US$330.00k | 0.0043% $ 841.9k | |
| Independent Director | 7.3yrs | US$327.87k | 0.0084% $ 1.6m | |
| Independent Director | 6.4yrs | US$315.25k | 0.0078% $ 1.5m | |
| Independent Director | 1.2yrs | US$176.66k | 0.0011% $ 221.1k |
7.3yrs
평균 재임 기간
64yo
평균 연령
경험이 풍부한 이사회: TEVA 의 이사회는 경험(평균 재직 기간 7.3 년)으로 간주됩니다.